Background: To study the mechanism of reproductive systemic toxicity of on SD rats.
Methods: The SD rats were randomly divided into groups and allocated three different treatments: control, 37.8 mg/kg Tripterygium glycosides, and 94.5 mg/kg Tripterygium glycosides, with each treatment applied for different lengths of time to 20 animals. Each group received treatment by intragastric administration once per day for 90 days. The estrus cycle was continuously observed throughout treatment. Animals were killed at each time point and analyses of sex hormones, sexual organ weights and coefficients, semen, pathology, and immunohistochemistry were conducted.
Results: The metestrus phase of the rats administered the low-dose and high-dose treatments was significantly decreased. The uterus organ-body coefficients of female rats were significantly increased, whereas the testis and epididymis organ-body and organ-brain coefficients in male rats were significantly decreased by the high-dose and low-dose treatments at different time points. An increase in immature sperm and sperm abnormality rate was observed at different times in the low-dose and high-dose groups. Pathological changes were clear in the testis, epididymis, ovary, and uterus. The levels of multiple hormones were significantly decreased. The hypothalamus estrogen receptor alpha (ER-α) receptor expression in female rats was also significantly decreased. The androgen receptor (AR) expression in the hypothalamus and the testis and epididymis was significantly decreased at different times by the high-dose treatment.
Conclusion: Tripterygium glycosides affected the estrus cycle in female rats and caused damage to the uterus; in male rats, the testicles and sperm were damaged. The mechanism of reproductive toxicity occurred through the secretion of multiple hormones.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The mechanisms of tripterygium glycosides-induced reproductive toxicity and detoxification strategies.
Reprod Toxicol
January 2025
Key Laboratory of Shaanxi Administration of Traditional Chinese Medicine for TCM Compatibility, Shaanxi University of Chinese Medicine, Xianyang 712046, Shaanxi Province, China. Electronic address:
Tripterygium glycosides (TG) is a widely used preparation in the treatment of rheumatoid arthritis (RA), nephrotic syndrome and diabetic nephropathy. Although the clinical efficacy is definite, the side-effects on reproductive system limit its wide application. It is of great significance to take measures to alleviate its reproductive toxicity and expand its clinical use.
View Article and Find Full Text PDFClinical Features of Chinese Patients With Bullous Pemphigoid Induced by Immune Checkpoint Inhibitors.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao
December 2024
Department of Dermatology,State Key Laboratory of Complex Severe and Rare Diseases,PUMC Hospital,CAMS and PUMC, National Clinical Research Center for Dermatologic and Immunologic Diseases,Beijing 100730,China.
Objective To explore the clinical features and treatments of Chinese patients with bullous pemphigoid (BP) induced by immune checkpoint inhibitors (ICI). Methods A retrospective analysis was conducted on 18 Chinese patients with ICI-induced BP treated in the Peking Union Medical College Hospital and 14 Chinese patients with this disease reported in the literature.Furthermore,the research data of non-Chinese patients were used for comparison to outline the clinical features and treatment responses of the Chinese patients.
View Article and Find Full Text PDFTherapeutic effects of tripterygium glycosides on periodontitis: Exploring the role of ursolic acid and the RIPK3/NLRP3 signaling pathway.
Int Immunopharmacol
December 2024
Dental Disease Prevention and Treatment Center of Minhang District, Shanghai 201103, China. Electronic address:
Background: Periodontitis, a chronic inflammatory disease, poses challenges in treatment due to its complex etiology. Tripterygium glycosides (TGs), renowned for their immunosuppressive and anti-inflammatory capabilities, present a prospective therapeutic option for the management of periodontitis. This study delves into the therapeutic efficacy of TGs in periodontitis and reveals the fundamental mechanisms involved.
View Article and Find Full Text PDFThe role and mechanism of triptolide, a potential new DMARD, in the treatment of rheumatoid arthritis.
Ageing Res Rev
December 2024
The First Clinical Medical College, Nanjing University of Chinese Medicine, No. 138 Xianlin Avenue, Nanjing 210023, China. Electronic address:
Triptolide (TP) is the primary pharmacological component of Tripterygium Glycosides (TG), which has anti-inflammatory, antiproliferative, and immunosuppressive properties, among other pharmacological actions, and has excellent potential for developing into a new DMARD. We have reviewed the effects and mechanisms of TP on immunosuppression, inhibiting synovial proliferation, and preventing articular bone destruction in the treatment of rheumatoid arthritis (RA), which is a common disease in the elderly in this paper. We have found that TP has regulatory effects on multiple vital cells in the above-mentioned pathological process of RA, such as monocytes/macrophages, dendritic cells, T cells, fibroblast-like synoviocytes, and osteoclasts.
View Article and Find Full Text PDFThis study explored the effect of Tripterygium glycosides(TG) on ulcerative colitis in rats and examined the regulatory role of the extracellular signal-regulated kinase/p38 mitogen-activated protein kinase(ERK/p38 MAPK) signaling pathway. Seventy male Wistar rats were selected and randomly divided into control, model, low-dose TG, medium-dose TG, high-dose TG, positive control, and pathway inhibitor groups. The disease activity index(DAI) score, macroscopic damage score, and microscopic colonic injury score were observed in each group.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!